Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Taxotere
TAXOTERE 20 mg/0.5 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 11
HOS-084527 · Präparat HOS-083047
Docetaxel is highly protein bound (> 95%). Although the possible in vivo interaction of docetaxel
with concomitantly administered medicinal product has not been investigated formally, in vitro
interactions with tightly protein-bound agents such as erythromycin, diphenhydramine, propranolol,
propafenone, phenytoin, salicylate, sulfamethoxazole and sodium valproate did not affect protein
binding of docetaxel. In addition, dexamethasone did not affect protein binding of docetaxel.
Docetaxel did not influence the binding of digitoxin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) propafenone (HOS-084530) salicylate (HOS-084532) digitoxin (HOS-084536) dexamethasone (HOS-084535) sodium valproate (HOS-084534) erythromycin (HOS-084514) propranolol (HOS-084529) diphenhydramine (HOS-084528) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 58e74626d940ed812319deed799a7721315c30830253c6e9d9e336dd8eb8520b · Zeichen 1567–2103 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 80 mg/2 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 55
HOS-084652 · Präparat HOS-083047
Docetaxel is highly protein bound (> 95%). Although the possible in vivo interaction of docetaxel with
concomitantly administered medicinal product has not been investigated formally, in vitro interactions
with tightly protein-bound agents such as erythromycin, diphenhydramine, propranolol, propafenone,
phenytoin, salicylate, sulfamethoxazole and sodium valproate did not affect protein binding of
docetaxel. In addition, dexamethasone did not affect protein binding of docetaxel. Docetaxel did not
influence the binding of digitoxin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) propafenone (HOS-084530) salicylate (HOS-084532) digitoxin (HOS-084536) dexamethasone (HOS-084535) sodium valproate (HOS-084534) erythromycin (HOS-084514) propranolol (HOS-084529) diphenhydramine (HOS-084528) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 62fb1b481dfc0759f1aa046a9bce8ee9fb6265ca121c8580de5e5c68a521d423 · Zeichen 1567–2103 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 20 mg/1 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 100
HOS-084766 · Präparat HOS-083047
Docetaxel is highly protein bound (> 95%). Although the possible in vivo interaction of docetaxel with
concomitantly administered medicinal product has not been investigated formally, in vitro interactions
with tightly protein-bound agents such as erythromycin, diphenhydramine, propranolol, propafenone,
phenytoin, salicylate, sulfamethoxazole and sodium valproate did not affect protein binding of
docetaxel. In addition, dexamethasone did not affect protein binding of docetaxel. Docetaxel did not
influence the binding of digitoxin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) propafenone (HOS-084530) salicylate (HOS-084532) digitoxin (HOS-084536) dexamethasone (HOS-084535) sodium valproate (HOS-084534) erythromycin (HOS-084514) propranolol (HOS-084529) diphenhydramine (HOS-084528) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 62fb1b481dfc0759f1aa046a9bce8ee9fb6265ca121c8580de5e5c68a521d423 · Zeichen 1567–2103 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 80 mg/4 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 144
HOS-084878 · Präparat HOS-083047
Docetaxel is highly protein bound (> 95%). Although the possible in vivo interaction of docetaxel with
concomitantly administered medicinal product has not been investigated formally, in vitro interactions
with tightly protein-bound agents such as erythromycin, diphenhydramine, propranolol, propafenone,
phenytoin, salicylate, sulfamethoxazole and sodium valproate did not affect protein binding of
docetaxel. In addition, dexamethasone did not affect protein binding of docetaxel. Docetaxel did not
influence the binding of digitoxin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) propafenone (HOS-084530) salicylate (HOS-084532) digitoxin (HOS-084536) dexamethasone (HOS-084535) sodium valproate (HOS-084534) erythromycin (HOS-084514) propranolol (HOS-084529) diphenhydramine (HOS-084528) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 62fb1b481dfc0759f1aa046a9bce8ee9fb6265ca121c8580de5e5c68a521d423 · Zeichen 1567–2103 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 160 mg/8 mL concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 189
HOS-084988 · Präparat HOS-083047
Docetaxel is highly protein bound (> 95%). Although the possible in vivo interaction of docetaxel with
concomitantly administered medicinal product has not been investigated formally, in vitro interactions
with tightly protein-bound agents such as erythromycin, diphenhydramine, propranolol, propafenone,
phenytoin, salicylate, sulfamethoxazole and sodium valproate did not affect protein binding of
docetaxel. In addition, dexamethasone did not affect protein binding of docetaxel. Docetaxel did not
influence the binding of digitoxin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) propafenone (HOS-084530) salicylate (HOS-084532) digitoxin (HOS-084536) dexamethasone (HOS-084535) sodium valproate (HOS-084534) erythromycin (HOS-084514) propranolol (HOS-084529) diphenhydramine (HOS-084528) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 62fb1b481dfc0759f1aa046a9bce8ee9fb6265ca121c8580de5e5c68a521d423 · Zeichen 1567–2103 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-086138 · Präparat HOS-083284
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) quetiapine (HOS-086150) encainide (HOS-086145) alfuzosin (HOS-086139) propafenone (HOS-084530) dronedarone (HOS-086144) fusidic acid (HOS-086146) bepridil (HOS-085612) quinidine (HOS-085593) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) clozapine (HOS-086149) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9fe97979894eedcce9660008265f9fc818cdb3984974bb2555b6c5e5869e4e5 · Zeichen 902–5292 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 35–36
HOS-086388 · Präparat HOS-083284
35
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecainide,
encainide, flecainide, propafenone, quinidine. Thereby, increasing
propafenone, quinidine the risk of arrhythmias or other serious adverse
effects from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Ergot Derivatives Dihydroergotamine, Increased plasma concentrations of ergot
ergonovine, derivatives leading to acute ergot toxicity,
ergotamine, including vasospasm and ischaemia.
methylergonovine
GI motility agent Cisapride Increased plasma concentrations of cisapride.
Thereby, increasing the risk of serious
arrhythmias from this agent.
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) quetiapine (HOS-086150) encainide (HOS-086145) methylergonovine (HOS-086155) propafenone (HOS-084530) dronedarone (HOS-086144) cisapride (HOS-085610) fusidic acid (HOS-086146) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) clozapine (HOS-086149) ergotamine (HOS-086154) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) ergonovine (HOS-086153) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f76b82bf2af9e33f5778d35af3ff4a8ea2ea8d392666af7950204db67ec4ac88 · Zeichen 1234–5743 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 13
HOS-086202 · Präparat HOS-083284
Antiarrthymics
Amiodarone, bepridil, dronedarone, Ritonavir co-administration is likely to result in increased plasma concentrations of
encainide, flecainide, propafenone, amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone, and
quinidine quinidine and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): encainide (HOS-086145) propafenone (HOS-084530) dronedarone (HOS-086144) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage db989a5b246ebda2c8effcb5a867688ba67111b2e2655b4b99403e29644def39 · Zeichen 13636–13987 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 45
HOS-086412 · Präparat HOS-083284
Antiarrthymics
Amiodarone, bepridil, dronedarone, Ritonavir co-administration is likely to result in increased plasma concentrations of
encainide, flecainide, propafenone, amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone, and quinidine and
quinidine is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): encainide (HOS-086145) propafenone (HOS-084530) dronedarone (HOS-086144) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 7be5a56d7eb28c6b0b362a7de5830a5d2ee65bd16f89e27afb151c7f671bb104 · Zeichen 13898–14249 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 7
HOS-109361 · Präparat HOS-093187
Effect of parecoxib (or its active metabolite valdecoxib) on the pharmacokinetics of other medicinal
products
Treatment with valdecoxib (40 mg twice daily for 7 days) produced a 3-fold increase in plasma
concentrations of dextromethorphan (CYP2D6 substrate). Therefore, caution should be observed when
coadministering Dynastat and medicinal products that are predominantly metabolised by CYP2D6 and
which have narrow therapeutic margins (e.g. flecainide, propafenone, metoprolol).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) flecainide (HOS-086203) dextromethorphan (HOS-109265) metoprolol (HOS-090094) valdecoxib (HOS-109357)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage b1ca6d2cd1226b59b1df3eb6dadfa83c841417205a1c6ed5f8fd8afe39274b41 · Zeichen 3695–4175 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 23
HOS-109408 · Präparat HOS-093187
Effect of parecoxib (or its active metabolite valdecoxib) on the pharmacokinetics of other medicinal
products
Treatment with valdecoxib (40 mg twice daily for 7 days) produced a 3-fold increase in plasma
concentrations of dextromethorphan (CYP2D6 substrate). Therefore, caution should be observed when
coadministering Dynastat and medicinal products that are predominantly metabolised by CYP2D6 and
which have narrow therapeutic margins (e.g. flecainide, propafenone, metoprolol).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) flecainide (HOS-086203) dextromethorphan (HOS-109265) metoprolol (HOS-090094) valdecoxib (HOS-109357)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage b1ca6d2cd1226b59b1df3eb6dadfa83c841417205a1c6ed5f8fd8afe39274b41 · Zeichen 3696–4176 im Abschnitt
Wechselwirkungen · Yentreve
YENTREVE 20 mg hard gastro-resistant capsules YENTREVE 40 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-112874 · Präparat HOS-093777
Medicinal products metabolised by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6. When
duloxetine was administered at a dose of 60 mg twice daily with a single dose of desipramine, a
CYP2D6 substrate, the AUC of desipramine increased 3-fold. The co-administration of duloxetine
(40 mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does
not affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is
recommended. Caution is advised if YENTREVE is co-administered with medicinal products that are
predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs] such as
nortriptyline, amitriptyline, and imipramine) particularly if they have a narrow therapeutic index (such
as flecainide, propafenone and metoprolol).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) propafenone (HOS-084530) tolterodine (HOS-087792) amitriptyline (HOS-085911) desipramine (HOS-086249) flecainide (HOS-086203) imipramine (HOS-085907) risperidone (HOS-086280) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 d927c7a519b8bbcba3c7ad828fbbce3643ea8a3886fcc0403d91cbec6695f99d · Passage f5263b2aae78af8828902f00ed3e0c2dc4fa81db18866a0b8f1f78e73aa8af66 · Zeichen 2181–2995 im Abschnitt
Wechselwirkungen · Cymbalta
Cymbalta 30 mg hard gastro-resistant capsules Cymbalta 60 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-113277 · Präparat HOS-093901
Medicinal products metabolised by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6. When
duloxetine was administered at a dose of 60 mg twice daily with a single dose of desipramine, a
CYP2D6 substrate, the AUC of desipramine increased 3-fold. The co-administration of duloxetine (40
mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does not
affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is
recommended. Caution is advised if Cymbalta is co-administered with medicinal products that are
predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs] such as
nortriptyline, amitriptyline, and imipramine) particularly if they have a narrow therapeutic index (such
as flecainide, propafenone and metoprolol).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) propafenone (HOS-084530) tolterodine (HOS-087792) amitriptyline (HOS-085911) desipramine (HOS-086249) flecainide (HOS-086203) imipramine (HOS-085907) risperidone (HOS-086280) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:40:00Z · SHA-256 a3b2a486f9b4069e76d38032cad9e45c893ee290991d9c0e8b3ea325ef1c101c · Passage 184748d3a5fcda9339ead3f2521f29c9a83708c878d80bf6315817d557c04e72 · Zeichen 2367–3181 im Abschnitt
Gegenanzeigen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-114797 · Präparat HOS-094169
Co-administration of Aptivus with low dose ritonavir, with active substances that are highly dependent
on CYP3A for clearance, and for which elevated plasma concentrations are associated with serious
and/or life-threatening events. These active substances include antiarrhythmics (such as amiodarone,
bepridil, quinidine), antihistamines (such as astemizole, terfenadine), ergot derivatives (such as
dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (such
as cisapride), antipsychotics (such as pimozide, sertindole, quetiapine, lurasidone), sedatives/hypnotics
(such as orally administered midazolam and triazolam) and HMG-CoA reductase inhibitors (such as
simvastatin and lovastatin) (see section 4.5). Also the use of the alpha-1 adrenoceptor antagonist
alfuzosin, and sildenafil when used for the treatment of pulmonary arterial hypertension. In addition,
co-administration of Aptivus with low dose ritonavir, and medicinal products that are highly
dependent on CYP2D6 for clearance, such as the antiarrhythmics flecainide, propafenone and
metoprolol given in heart failure (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) alfuzosin (HOS-086139) methylergonovine (HOS-086155) propafenone (HOS-084530) cisapride (HOS-085610) lovastatin (HOS-086157) flecainide (HOS-086203) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) metoprolol (HOS-090094) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 899ebcf3829943bae5ad39416161803c04f5d7f21f78b5a86a8cc0fb492896e8 · Zeichen 519–1660 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 19–20
HOS-114844 · Präparat HOS-094169
19
H2-receptor antagonists
No interaction study No data are available for An increase in gastric pH that
performed H2-receptor antagonists in may result from H2-receptor
combination with tipranavir and antagonist therapy is not expected
low dose ritonavir. to have an impact on tipranavir
plasma concentrations.
Antiarrhythmics
Amiodarone Based on theoretical The concomitant use of Aptivus,
Bepridil considerations, tipranavir, co- co-administered with low dose
Quinidine administered with low dose ritonavir, with amiodarone,
No interaction study ritonavir, is expected to increase bepridil or quinidine is
performed amiodarone, bepridil and contraindicated due to potential
quinidine concentrations. serious and/or life threatening
events (see section 4.3)
Inhibition of CYP 3A4 by
tipranavir/r
Flecainide Based on theoretical The concomitant use of Aptivus,
Propafenone considerations, tipranavir, co- co-administered with low dose
Metoprolol (given in heart administered with low dose ritonavir, with flecainide,
failure) ritonavir, is expected to increase propafenone or metoprolol is
No interaction study flecainide, propafenone and contraindicated (see section 4.3)
performed metoprolol concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) ritonavir (HOS-084521) amiodarone (HOS-085596) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 6aa9e00d4b58261863af53d4fabbddef6456a645d8623cbe7ba0ff2c874fe543 · Zeichen 48623–50469 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 10
HOS-116324 · Präparat HOS-094447
A clinical study utilising a cocktail of medicinal products that are metabolised by cytochromes
CYP2C9, CYP2C19 and CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and
inhibition of CYP2D6 activity in the presence of darunavir/ritonavir, which may be attributed to the
presence of low dose ritonavir. Co-administration of darunavir and ritonavir with medicinal products
which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result
in increased plasma concentrations of these medicinal products, which could increase or prolong their
therapeutic effect and adverse reactions. Co-administration of darunavir and ritonavir with medicinal
products primarily metabolised by CYP2C9 (such as warfarin) and CYP2C19 (such as methadone)
may result in decreased systemic exposure to such medicinal products, which could decrease or
shorten their therapeutic effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) methadone (HOS-086198) flecainide (HOS-086203) ritonavir (HOS-084521) metoprolol (HOS-090094) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 1c69c1e904c5e45f21197cc74aaf3793a744795efd05ba12ed65d139c93b2ca1 · Zeichen 3809–4716 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 14–15
HOS-116357 · Präparat HOS-094447
14
HIV Protease inhibitors (PIs) - with co-administration of low dose ritonavir†
Lopinavir/ritonavir lopinavir AUC ↑ 9% Due to a decrease in the exposure
400/100 mg twice daily lopinavir Cmin ↑ 23% (AUC) of darunavir by 40%,
lopinavir Cmax ↓ 2% appropriate doses of the
darunavir AUC ↓ 38% ‡ combination have not been
darunavir Cmin ↓ 51% ‡ established. Hence, concomitant
‡ use of boosted PREZISTA and the
darunavir Cmax ↓ 21%
Lopinavir/ritonavir combination product
lopinavir AUC ↔
533/133.3 mg twice daily lopinavir/ritonavir is
lopinavir Cmin ↑ 13% contraindicated (see section 4.3).
lopinavir Cmax ↑ 11%
darunavir AUC ↓ 41%
darunavir Cmin ↓ 55%
darunavir Cmax ↓ 21%
‡
based upon non dose normalised values
CCR5 ANTAGONIST
Maraviroc maraviroc AUC ↑ 305% The maraviroc dose should be
150 mg twice dailymaraviroc Cmin ND 150 mg twice daily when
maraviroc Cmax ↑ 129% co-administered with boosted
darunavir, ritonavir concentrations were PREZISTA.
consistent with historical data
α1-ADRENORECEPTOR ANTAGONIST
Alfuzosin Based on theoretical considerations Co-administration of boosted
PREZISTA is expected to increase PREZISTA and alfuzosin is
alfuzosin plasma concentrations. contraindicated (see section 4.3).
(CYP3A inhibition)
ANAESTHETIC
Alfentanil Not studied. The metabolism of alfentanil The concomitant use with boosted
is mediated via CYP3A, and may as such PREZISTA may require to lower
be inhibited by boosted PREZISTA. the dose of alfentanil and requires
monitoring for risks of prolonged
or delayed respiratory depression.
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Not studied. Boosted PREZISTA is Caution is warranted and
Flecainide expected to increase these antiarrhythmic therapeutic concentration
Lidocaine (systemic) plasma concentrations. monitoring, if available, is
Mexiletine (CYP3A and/or CYP2D6 inhibition) recommended for these
Propafenone antiarrhythmics when
co-administered with boosted
PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) lopinavir (HOS-086269) propafenone (HOS-084530) protease (HOS-085623) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) disopyramide (HOS-085595) maraviroc (HOS-086186) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 79aee1bbebf74d1fc7eeb1f64d47f744ae971edc2caad3984bd946f3f467a703 · Zeichen 24118–27577 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52
HOS-116503 · Präparat HOS-094447
A clinical study utilising a cocktail of medicinal products that are metabolised by cytochromes
CYP2C9, CYP2C19 and CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and
inhibition of CYP2D6 activity in the presence of darunavir/ritonavir, which may be attributed to the
presence of low dose ritonavir. Co-administration of darunavir and ritonavir with medicinal products
which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result
in increased plasma concentrations of these medicinal products, which could increase or prolong their
therapeutic effect and adverse reactions. Co-administration of darunavir and ritonavir with medicinal
products primarily metabolised by CYP2C9 (such as warfarin) and CYP2C19 (such as methadone)
may result in decreased systemic exposure to such medicinal products, which could decrease or
shorten their therapeutic effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) methadone (HOS-086198) flecainide (HOS-086203) ritonavir (HOS-084521) metoprolol (HOS-090094) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 1c69c1e904c5e45f21197cc74aaf3793a744795efd05ba12ed65d139c93b2ca1 · Zeichen 1418–2325 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 56–57
HOS-116516 · Präparat HOS-094447
56
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Not studied. PREZISTA is expected to Caution is warranted and
Flecainide increase these antiarrhythmic plasma therapeutic concentration
Lidocaine (systemic) concentrations. monitoring, if available, is
Mexiletine (CYP3A and/or CYP2D6 inhibition) recommended for these
Propafenone antiarrhythmics when
co-administered with PREZISTA
with low dose ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) disopyramide (HOS-085595) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 57e505293229728296e7dd8480ad0507531ed8d1e94d1f9e07e41fe182a75b64 · Zeichen 20406–21075 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 92
HOS-116591 · Präparat HOS-094447
A clinical study utilising a cocktail of medicinal products that are metabolised by cytochromes
CYP2C9, CYP2C19 and CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and
inhibition of CYP2D6 activity in the presence of darunavir/ritonavir, which may be attributed to the
presence of low dose ritonavir. Co-administration of darunavir and ritonavir with medicinal products
which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result
in increased plasma concentrations of these medicinal products, which could increase or prolong their
therapeutic effect and adverse reactions. Co-administration of darunavir and ritonavir with medicinal
products primarily metabolised by CYP2C9 (such as warfarin) and CYP2C19 (such as methadone)
may result in decreased systemic exposure to such medicinal products, which could decrease or
shorten their therapeutic effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) methadone (HOS-086198) flecainide (HOS-086203) ritonavir (HOS-084521) metoprolol (HOS-090094) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 1c69c1e904c5e45f21197cc74aaf3793a744795efd05ba12ed65d139c93b2ca1 · Zeichen 3807–4714 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.